Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia [Corrigendum]
Authors Hoggatt J, Tate TA, Pelus LM
Received 22 April 2015
Accepted for publication 22 April 2015
Published 27 August 2015 Volume 2015:10(1) Pages 5421—5422
Hoggatt J, Tate TA, Pelus LM. Int J Nanomed. 2015;10:2647–2652.
In this article, Lipegfilgrastim was referred to as a "long-acting biosimilar filgrastim". The term "biosimilar" was used too broadly in this case, as Lipegfilgrastim was not approved under the biosimilar classification by the EMA. Rather, lipegfilgrastim has an active substance that is similar to filgrastim, with similar pharmacokinetics, receptor binding affinity, safety and efficacy as pegfilgrastim.
Read the original article
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]